Leukemia Clinical Trial
Official title:
A Combination of PKC412 and 5-Azacytidine for the Treatment of Patients With Refractory or Relapsed Acute Leukemia and Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if the combination of PKC412 (also called Midostaurin) and 5-azacytidine can help to control refractory or relapsed acute leukemia and MDS. The safety and best dose of the combination of the drugs will also be studied.
The Study Drugs:
PKC412 is designed to block certain receptors (FLT3-Kinase) on cancer cells that are
responsible for cancer growth. This may cause the cancer cells to die.
5-azacytidine is designed to cause changes to certain genes that are thought to participate
in causing leukemia. These changes are thought to silence these genes so they cannot
contribute any longer to sustain the growth of leukemia and MDS.
Study Groups:
If you are found to be eligible to take part in this study, you will be assigned to a part of
the study based on when you join.
- If you are one of the first 6 participants, you will receive a pre-planned dose of the
study drugs. If 2 participants experience severe side effects, the rest of this group
will receive a lower dose.
- If you are not one of the first 6 participants, and fewer than 2 patients had severe
side effects in the first group, you will receive the drugs at a higher dose than the
first 6 participants.
Study Drug Administration:
You will receive 5-azacytidine by vein over about 30 minutes or through a needle under your
skin on Days 1-7 of each 28-day study cycle. Your doctor will decide if you will get the drug
by vein or under the skin. You will be required to return to MD Anderson for the first 7 days
of every cycle to receive 5-azacytidine.
On Days 8-21 of cycle 1, you will take PKC412 capsules by mouth 2 times a day. Starting with
Cycle 2, you will take PKC412 capsules by mouth every day. The research staff will tell you
how to take the study drug and you will also be given instructions.
If you have severe side effects from the study drug, the study doctor may decide to stop drug
dosing until your side effects improve.
Study Visits:
At every visit, you will be asked about any side effects you have experienced and to list any
drugs you may be taking.
- At the start of Cycles 1-2 (+/- 4 days) and then every 2-3 cycles, you will have a
complete physical exam.
- Every week during Cycles 1-3 (+/- 4 days) and then every 2-4 weeks, blood (about 1
tablespoon) will be drawn for routine tests and to test your kidney and liver function.
- On Day 28 of Cycle 1 (+/- 4 days) and then every 1-3 cycles, you will have a bone marrow
aspirate to check the status of the disease.
- On Day 8 (+/- 1 day) of each cycle for the first cycle before initiation of Midostaurin,
then before the start of Midostaurin on Cycle 2, then on Day 1 every 2-3 Cycles, you
will have an ECG.
- On Days 8, 15, and 21 of Cycle 1 and Day 1 of Cycle 2, blood (about 1 teaspoon) will be
drawn for Pharmacokinetic (PK) testing before you take the study drug.
If you stay on study for longer than 6 months, your doctor will decide what tests and
procedures you will have and when they will be performed. At least every 6-12 months you will
have a bone marrow aspirate.
Length of Study:
You may continue taking the study drug for as long as the doctor thinks it is in your best
interest. You will no longer be able to take the study drug if the disease gets worse or
intolerable side effects occur.
This is an investigational study. PKC412 is not FDA approved or commercially available. It is
currently being used for research purposes only. 5-azacytidine is FDA approved and
commercially available for the treatment of patients with MDS. The combination of these drugs
to treat refractory or relapsed acute leukemia and MDS is investigational.
Up to 54 patients will take part in this study. All will be enrolled at MD Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |